Evidence map›Paper›PMID 40454371›Full record

Review3 Biotech2025

Exploring the neuroprotective role of

Mohd Nadeem, Mohd Ashif Khan, Farhan Jalees Ahmad, Suhel Parvez, Mohd Akhtar, Abul Kalam Najmi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohd NadeemDepartment of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062 India.
Mohd Ashif KhanDepartment of Translational and Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, 110062 India.
Farhan Jalees AhmadDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062 India.
Suhel ParvezDepartment of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, 110062 India.
Mohd AkhtarDepartment of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062 India.
Abul Kalam NajmiDepartment of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062 India.ORCID 0000-0002-9299-414X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD), a progressive neurodegenerative disease, is characterized by cognitive decline, memory loss, and pathological features such as amyloid-beta plaques, tau hyperphosphorylation, oxidative stress, and neuroinflammation. Current therapies do not adequately address the disease's fundamental causes, even while they provide symptomatic relief.

Indexed as

Alzheimer’s diseaseAmyloid-betaAsparagus racemosusBioactive compoundsNeurodegenerative diseaseShatavari

Identifiers

PMID40454371
PMCPMC12125427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.